Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 06, 2020 16:05 ET | Source: BeiGene, LTD.

BeiGene Reports Second Quarter 2020 Financial Results

CAMBRIDGE, Mass. and BEIJING, China, Aug. 06, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
August 05, 2020 07:00 ET | Source: BeiGene, LTD.

BeiGene Announces Data on Tislelizumab and Pamiparib to Be Presented at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress

CAMBRIDGE, Mass. and BEIJING, China, Aug. 05, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
July 27, 2020 09:15 ET | Source: BeiGene, LTD.

Priority Review Granted to BeiGene’s New Drug Application of Pamiparib in Ovarian Cancer in China

BEIJING, China and CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company, today announced that the Center for Drug...
July 17, 2020 09:00 ET | Source: BeiGene, LTD.

BeiGene Announces Acceptance of a New Drug Application of Pamiparib in Ovarian Cancer in China

BEIJING, China and CAMBRIDGE, Mass., July 17, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
July 15, 2020 17:00 ET | Source: BeiGene, LTD.

BeiGene Announces Closing of Approximately $2.08 Billion Registered Direct Offering

CAMBRIDGE, Mass. and BEIJING, China, July 15, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
July 12, 2020 20:00 ET | Source: BeiGene, LTD.

BeiGene Announces Pricing of Approximately $2.08 Billion Registered Direct Offering

CAMBRIDGE, Mass. and BEIJING, China, July 12, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
July 02, 2020 07:00 ET | Source: BeiGene, LTD.

BeiGene to Host Investor Conference Call and Webcast to Discuss the Company’s Early Development Pipeline and Research

CAMBRIDGE, Mass. and BEIJING, China, July 02, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
July 01, 2020 18:00 ET | Source: BeiGene, LTD.

BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Patients with Previously Treated Unresectable Hepatocellular Carcinoma in China

BEIJING, China and CAMBRIDGE, Mass., July 01, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
July 01, 2020 07:00 ET | Source: BeiGene, LTD.

BeiGene Announces Appointment of Angus Grant as Chief Business Executive

CAMBRIDGE, Mass. and BEIJING, China, July 01, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
June 30, 2020 19:30 ET | Source: BeiGene, LTD.

BeiGene Begins Commercializing XGEVA® (Denosumab) in China

BEIJING, China and CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...

Next Page keyboard_arrow_right